Biotech Values

[redfairway]

I have been told that no one rings a bell at the top or bottom of a stock move. But Teva's comments that they are stuck in limbo with their generic application is the loudest bell I have heard. The WSJ article is not a negative for MNTA despite the share price action; it is a negative for TEVA and a huge plus for MNTA. I think that by the next quarter, we will look back at today as the start of a huge stock move.